Human-derived immune globulins for the treatment of botulism.
The need for a human-derived immune globulin to replace the equine antitoxins currently used in the treatment of botulism is well recognized. A small group of individuals who had received multiple immunizations with pentavalent botulinal toxoid were plasmapheresed for the purpose of collecting a botulism-immune plasma of human origin to be fractionated for the production of immune globulin. Human-derived immune globulin will offer the advantage over equine antitoxins of not inducing reactions to foreign protein and of having a prolonged effective half-life.
D000818:Animals; D001904:Botulinum Antitoxin / Q000627:therapeutic use; D001906:Botulism / Q000517:prevention & control / Q000628:therapy*; D003014:Clostridium botulinum / Q000378:metabolism; D006736:Horses / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis / Q000627:therapeutic use*; D014121:Toxoids / Q000008:administration & dosage
D001904:Botulinum Antitoxin; D007136:Immunoglobulins; D014121:Toxoids